GlobeNewswire

Galapagos increases share capital through warrant exercise by Gilead

Share

Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from a warrant exercise by Gilead.

On 1 November 2019, Galapagos NV (the "Company" or "Galapagos") announced that Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ: GILD) ("Gilead"), delivered an exercise notice to Galapagos in order to exercise the Initial Warrant A.

Initial Warrant A, approved by Galapagos' shareholders on 22 October 2019, entitles the holder thereof to subscribe for a maximum number of shares that is sufficient to bring the number of shares owned by Gilead and any of its affiliates to 25.1% of the actually issued and outstanding shares immediately after the issue of the shares that are to be issued upon the relevant exercise of Initial Warrant A. Initial Warrant A has a term of one year starting as of 22 October 2019.

As a result of the exercise of the Initial Warrant A, Gilead subscribed for 2,617,791 shares at €140.59 per share for a total of €368,035,236.69. The new shares were issued on 6 November 2019.

In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €349,274,259.52, the total number of securities conferring voting rights is 64,571,622, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe for not yet issued securities conferring voting rights consists of (i) 5,636,297 warrants under several outstanding employee warrant plans, which equals 5,636,297 voting rights that may result from the exercise of those warrants, and (ii) two warrants issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead and its affiliates to 25.1% and 29.9%, respectively, of the actually issued and outstanding shares after the exercise of the relevant warrant. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contacts

Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Director Investor Relations
+32 485 19 14 15
ir@glpg.com

Media:
Carmen Vroonen
Senior Director Communications & Public Affairs
+32 473 824 874

Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com

Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These
forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.





1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions.



Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Sweden’s Första AP-fonden (AP1) Selects eVestment for Asset Manager Monitoring3.6.2020 09:00:10 CESTPress release

STOCKHOLM, Sweden and LONDON, June 03, 2020 (GLOBE NEWSWIRE) -- Swedish public pension fund Första AP-fonden (AP1) will add to its asset manager selection capabilities by adopting asset manager monitoring capabilities from eVestment, a global leader in institutional investment data and analytics. As pensions around the world search for investment returns at acceptable levels of risk, data providers like eVestment have an important role in collecting and organizing data used in the manager assessment and monitoring processes. With 4000+ asset managers from around the world reporting data to eVestment on more than 25,000 institutional strategies, eVestment offers the most comprehensive look at trends across the institutional landscape, at the universe, firm and product levels. “As a leading source of institutional manager data, both in local markets and globally, eVestment provides a holistic view of the managers and strategies available,” said eVestment Managing Director for EMEA J.P. Q

AP1 väljer eVestment som analysverktyg för externa kapitalförvaltare3.6.2020 09:00:10 CESTPressemelding

STOCKHOLM och LONDON, June 03, 2020 (GLOBE NEWSWIRE) -- Den statliga svenska pensionsfonden Första AP-fonden (AP1) inleder ett samarbete med eVestment som leverantör av data för analys av externa kapitalförvaltare. eVestment är en global ledare inom investeringsdata och investeringsanalys för institutionella investerare. När pensionsfonder över hela världen söker efter investeringsstrategier som ger avkastning till en given risknivå, är eVestment en viktig samarbetspartner för att samla in data för analys och för att organisera densamma. Över 4 000 kapitalförvaltare från hela världen levererar data till eVestment där mer än 25 000 institutionella strategier ingår. eVestment levererar en heltäckande översikt såväl på en övergripande nivå som på en företags- och produktnivå. – Som en av de ledande leverantörerna av data om institutionella förvaltare, hjälper eVestment till att ge en helhetsbild av tillgängliga förvaltare och strategier, både lokalt och globalt. Kontinuerlig uppföljning ä

Rovio Entertainment has acquired Darkfire Games - Copenhagen based mobile games studio3.6.2020 08:30:00 CESTPress release

Rovio Entertainment Corporation Press Release Rovio Entertainment has acquired Darkfire Games - Copenhagen based mobile games studio June 3, 2020 - Espoo - Rovio Entertainment Corp. has acquired a free-to-play (F2P) mobile games studio Darkfire Games (formerly Wargaming Denmark), focused on Role Playing Games (RPG). Rovio acquired all of the outstanding shares of Darkfire Games for an undisclosed sum on June 3, 2020, and the wholly-owned Rovio subsidiary will become Rovio Copenhagen. Rovio Copenhagen will continue to operate as an independent studio focusing on mobile RPGs. At present, the studio comprises 20 gaming industry veterans with vast expertise in making RPGs. As part of the acquisition, Rovio takes on the studio’s currently soft-launched mobile RPG, Darkfire Heroes. The game’s development will continue in Copenhagen, with Rovio providing synergies and support for the studio in central functions and areas such as user acquisition, technology, analytics and live operations. “We

Active Biotech tillhandahåller statusuppdatering i projekten3.6.2020 08:30:00 CESTPressemelding

Lund, 3 juni 2020 - Active Biotech (Nasdaq Stockholm: ACTI) tillhandahåller idag en statusuppdatering i projekten i och med den nya inriktningen som kommunicerades i början av februari. Denna förkortade uppdatering tillhandahålls som ersättning för den kapitalmarknadsdag som tidigare planerades till den 19 maj, och som vi istället avser att genomföra under det fjärde kvartalet i år med förbehåll för status avseende Covid-19. Trots Covid-19-pandemin har de flesta aktiviteterna i våra projekt genomförts planenligt och hittills har inga projekttidslinjer påverkats väsentligt. Fas 1b/2-studien med naptumomab i kombination med checkpoint-hämmaren durvalumab hos patienter med avancerad solida tumörer syftar till att fastställa maximalt tolererad dos av kombinationen innan man går vidare i en utvidgad kohort-studie i USA. Studien fortskrider enligt plan och vi ser fram emot att meddela resultaten från doseskaleringsfasen i denna studie senare i år. I tasquinimod-projektet, som är inriktat på

HOYLU AB: HOYLU FÅR NY ORDER FRÅN LÄKEMEDELSFÖRETAG3.6.2020 08:30:00 CESTPressemelding

Stockholm, Sverige, 3 juni 2020 – Hoylu, ledande inom visuella samarbetslösningar för distribuerade team, meddelade idag att man fått enny order från Foundation Medicine, en befintlig kund hos Hoylu inom läkemedelsindustrin. Ordervärdet uppgår till 380 000 kronor i mjukvaruintäkter. Hoylus mjukvara och lösningar erbjuder nya och spännande sätt att kommunicera och samarbeta smartare, snabbare och mer effektivt. Hoylu's Connected WorkspacesTM hjälper företagskunder att hantera sina aktiviteter, visualisera arbete och motivera människor att göra sitt bästa genom att undvika missförstånd och säkra framgång. För mer information kontakta: Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: sr@hoylu.com Karl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: kw@hoylu.com Hoylu AB Om Hoylu Hoylu s uppdrag är att göra distansarbete och informationsutbyte lätt. Genom våra anpassningsbara Connected Workspaces™ levererar vi programvarulösningar för företag, organisationer och individer i praktiskt tag

Ernst Jansen new COO of Kempen Capital Management3.6.2020 08:30:00 CESTPress release

Amsterdam/’s-Hertogenbosch, the Netherlands, 3 June 2020 Ernst Jansen has been appointed Chief Operating Officer (COO) at Kempen Capital Management (Kempen) with immediate effect. The successor to Erik Luttenberg, Jansen will take on this role alongside his current position of COO of Van Lanschot Private Banking. The new position also sees him appointed to Kempen’s Management Board. Constant Korthout, Van Lanschot Kempen’s Chief Financial Officer and Chief Risk Officer (CFO/CRO), explained: “We’re very pleased that Ernst has proved willing to take on these new responsibilities alongside his current position. This appointment reflects our strategy towards a fully integrated wealth management model by 2023, allowing us to enhance our efficiency and productivity, and act as a single group. Our thanks go to Erik for his many years of service to our organisation, and we wish Ernst lots of success in his new role.” Media Relations: +31 20 354 45 85; mediarelations@vanlanschotkempen.com Inves